# A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB)

> **NCT02345213** · PHASE4 · COMPLETED · sponsor: **Eisai Co., Ltd.** · enrollment: 160 (actual)

## Conditions studied

- Dementia, Lewy Body
- Lewy Body Disease

## Interventions

- **DRUG:** E2020
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02345213
- **Lead sponsor:** Eisai Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-01
- **Primary completion:** 2017-05-15
- **Final completion:** 2018-03-26
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2019-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02345213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02345213, "A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB)". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT02345213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*